Many clinical guidelines recommend thiazide diuretics as first-line treatment for hypertension, even in individuals with mild chronic kidney disease (CKD). However, results from the ACCOMPLISH trial add to growing evidence that thiazide-based therapy does not retard progression of CKD. Re-evaluation of the role of these agents in the management of hypertension in patients with CKD might be appropriate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chobanian, A. V. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560–2572 (2003).
[No authors listed] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981–2997 (2002).
Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417–2428 (2008).
Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173–1181 (2010).
Lindholm, L. H. et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. 21, 1563–1574 (2003).
Perkins, B. A. et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 77, 57–64 (2010).
Hawkins, R. G. & Houston, M. C. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am. J. Hypertens. 18, 744–749 (2005).
Reungjui, S. et al. Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int. 72, 1483–1492 (2007).
Loffing, J. et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int. 50, 1180–1190 (1996).
Reungjui, S. et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J. Am. Soc. Nephrol. 18, 2724–2731 (2007).
Acknowledgements
The authors' research work is supported in part by NIH HL-68607 and HL-79352.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nakagawa, T., Johnson, R. Is there a dark side to thiazide therapy for hypertension?. Nat Rev Nephrol 6, 564–566 (2010). https://doi.org/10.1038/nrneph.2010.114
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.114
This article is cited by
-
Which Diuretic Is the Preferred Agent for Treating Essential Hypertension: Hydrochlorothiazide or Chlorthalidone?
Current Cardiology Reports (2012)
